Revolution Medicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	11.58	35.38	29.39	42.98	50.04	20.17	0
Revenue Growth (YoY)	-67.27%	20.38%	-31.62%	-14.10%	148.16%	-	-
Gross Profit	11.58	35.38	29.39	42.98	50.04	20.17	0
Selling, General & Admin	75.62	40.59	30.45	21.43	12.41	9.41	4.54
Research & Development	423.14	253.07	186.95	132.25	91.76	51.08	26.59
Operating Expenses	498.77	293.66	217.4	153.68	104.16	60.49	31.13
Operating Income	-487.19	-258.28	-188.01	-110.7	-54.12	-40.33	-31.13
Interest Expense / Income	0.3	0	0.01	0.07	0.11	0.12	0.1
Other Expense / Income	-47.6	-9.15	-0.93	-2.24	-2.19	1.34	-0.11
Pretax Income	-439.89	-249.13	-187.09	-108.53	-52.04	-41.79	-31.13
Income Tax	-3.52	-0.42	0	-0.37	-4.37	0	0
Net Income	-436.37	-248.71	-187.09	-108.16	-47.66	-41.79	-31.13
Preferred Dividends	0	0	0	2.22	14.24	7.03	3.76
Net Income Common	-436.37	-248.71	-187.09	-110.38	-61.9	-48.82	-34.89
Shares Outstanding (Basic)	113	81	73	55	3	2	2
Shares Outstanding (Diluted)	113	81	73	55	3	2	2
Shares Change	40.34%	10.74%	32.68%	1879.17%	20.61%	33.39%	-
EPS (Basic)	-3.86	-3.08	-2.57	-2.01	-22.33	-21.24	-20.25
EPS (Diluted)	-3.86	-3.08	-2.57	-2.01	-22.33	-21.24	-20.25
Free Cash Flow	-358.3	-235.22	-153.71	-103	-52.01	-0.29	-26.72
Free Cash Flow Per Share	-3.17	-2.92	-2.11	-1.88	-18.76	-0.12	-15.51
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-4207.12%	-730.01%	-639.70%	-257.54%	-108.15%	-200.00%	-
Profit Margin	-3768.28%	-702.95%	-636.58%	-256.79%	-123.70%	-242.10%	-
Free Cash Flow Margin	-3094.14%	-664.83%	-522.99%	-239.62%	-103.93%	-1.42%	-
EBITDA	-430.28	-239.47	-179.75	-101.91	-48.59	-39.91	-29.84
EBITDA Margin	-3715.71%	-676.85%	-611.59%	-237.10%	-97.10%	-197.91%	-
Depreciation & Amortization	9.31	9.66	7.33	6.55	3.34	1.76	1.19
EBIT	-439.59	-249.13	-187.08	-108.46	-51.93	-41.67	-31.02
EBIT Margin	-3796.10%	-704.14%	-636.54%	-252.33%	-103.78%	-206.66%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).